◀ Back to TP53
PSENEN — TP53
Text-mined interactions from Literome
Alves da Costa et al., J Neurosci 2006
(Alzheimer Disease) :
We demonstrate that PS deficiency, catalytically inactive PS mutants,
gamma-secretase inhibitors, and betaAPP or amyloid precursor protein-like protein 2 ( APLP2 ) depletion all
reduce the expression and activity of
p53 and lower the transactivation of its promoter and mRNA expression
Checler et al., Curr Alzheimer Res 2007
:
Thus, we established that PS deficiency, catalytically inactive PS mutants,
gamma-secretase inhibitors and betaAPP or APLP2 depletion
reduced the expression and activity of
p53 , and lowered the transactivation of its promoter and mRNA levels